IAP Inhibitor Development Services for Cancer
Alfa Cytology is a company focused on providing comprehensive preclinical research and development services for the advancement of cancer therapies. Our services are focused on meeting the urgent need for innovative cancer therapies and are designed to accelerate the development and optimization of novel IAP inhibitors for a wide range of malignancies.
Introduction to IAP Inhibitor for Cancer
Inhibitors of apoptosis (IAP) are a family of proteins that regulate apoptosis (programmed cell death) and play an important role in cancer cell survival and resistance to cell death. IAP inhibitors are drugs designed to target these proteins. By blocking the function of the IAP proteins, these inhibitors induce apoptosis or sensitize cancer cells to chemotherapy or radiotherapy to enhance their efficacy. They can also sensitize cancer cells to chemotherapy or radiotherapy to enhance their efficacy. In addition, IAP inhibitors can cause immune-mediated destruction of tumors by enhancing the anti-cancer immune response.
Fig.1 The role of inhibition of apoptosis proteins (IAPs) and their physiological and pharmacological inhibitors. (Barroso, T., et al., 2021)
Examples of IAP Inhibitors
Common examples of IAP inhibitors include smac (second mitochondria-derived activator of caspases) mimetics, embelin, birinapine, and other drugs, which have shown promise in early studies for the therapy of melanoma, pancreatic cancer and cancers such as lymphoma and myeloma.
Our Services
Through innovative research and advanced technology, Alfa Cytology delves into the mechanism of action of IAP inhibitors and has the ability to help customers develop novel IAP inhibitors, as well as optimize the effectiveness of IAP inhibitors and identify their biomarkers, to facilitate the advancement of IAP-targeted cancer therapies.
One-stop Solutions for IAP Inhibitor Development
Alfa Cytology offers a range of services to support the development of IAP inhibitors for use in cancer therapy, including but not limited to the following.
Target Identification and Validation
Utilizing bioinformatics tools and functional assays to identify and validate IAPs as therapeutic targets in specific cancer types.
Hit Identification and Optimization
Employing virtual screening, fragment-based drug design, and medicinal chemistry approaches to discover and optimize lead compounds with potent IAP inhibitory activity.
Biological Assays Development
Developing and optimizing cellular and biochemical assays to evaluate the efficacy, selectivity, and mechanism of action of IAP inhibitors.
In Vivo Models Selection
Utilizing patient-derived xenograft (PDX) models and genetically engineered mouse models (GEMMs) to assess the in vivo efficacy and pharmacodynamics of IAP inhibitors.
PK/PD Studies
Conducting PK/PD studies to characterize the absorption, distribution, metabolism, and excretion profiles of IAP inhibitors and their impact on target engagement and downstream signaling pathways.
Safety Assessment
Performing comprehensive safety pharmacology and toxicology studies to evaluate the safety profile and potential adverse effects of IAP inhibitors.
Targets for IAP Inhibitor Development
Our IAP inhibitor development services target the following key molecules and pathways involved in cancer. We are dedicated to assisting in the development of targeted therapies across multiple molecule types, including small molecule inhibitors, monoclonal antibodies, polyclonal antibodies, vaccines and others.
Development Types Targeting XIAP
- Small molecule inhibitors
- Monoclonal antibodies
- SMAC mimetics
Development Types Targeting cIAP1
- Small molecule inhibitors
- Monoclonal antibodies
- cIAP1 degraders
Development Types Targeting NF-κB Pathway
- Small molecule inhibitors
- Monoclonal antibodies
- NF-κB modulators
Alfa Cytology is a company dedicated to the development of cancer cell therapies. We primarily serve researchers engaged in the development of next-generation therapies worldwide, providing them with services and solutions related to preclinical research. Contact us today to learn more about how we can work together to bring your therapy vision to life.
Reference
- Barroso, T., et al.; (2023). Targeting Inhibitor of Apoptosis Proteins to Overcome Chemotherapy Resistance—A Marriage between Targeted Therapy and Cytotoxic Chemotherapy. International Journal of Molecular Sciences, 24(17), 13385.
! For research use only.
Related Services
